

SANOFI-AVENTIS
Form 6-K
February 08, 2007
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2007

Commission File Number: 001-31368

SANOFI-AVENTIS

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form	Form
20-F <input checked="" type="checkbox"/>	40-F <input type="checkbox"/>

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Edgar Filing: SANOFI-AVENTIS - Form 6-K

Yes No

If Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

In January and February 2007, sanofi-aventis issued the press releases attached hereto as Exhibit 99.1, 99.2, 99.3 and 99.4 which are incorporated herein by reference.

Exhibit List

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press release dated January 19, 2007 S-1 oral anticancer agent improves patients survival in adjuvant gastric cancer trial versus surgery alone
Exhibit 99.2	Press release dated January 25, 2007 FDA Advisory Committee Recommends Licensure of New Pediatric Combination Vaccine
Exhibit 99.3	Press release dated February 6, 2007 Positive Recommendation for Acomplia® from the Transparency Committee in France
Exhibit 99.4	Press release dated February 6, 2007 FDA Grants Priority Review to Lovenox® (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for additional type of heart attack .

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 8, 2006

SANOFI-AVENTIS

By: /s/ Patricia Kodyra _____
Name: Patricia Kodyra
Title: Associate Vice President
Financial and Securities Law

3

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press release dated January 19, 2007 S-1 oral anticancer agent improves patients' survival in adjuvant gastric cancer trial versus surgery alone
Exhibit 99.2	Press release dated January 25, 2007 FDA Advisory Committee Recommends Licensure of New Pediatric Combination Vaccine
Exhibit 99.3	Press release dated February 6, 2007 Positive Recommendation for Acomplia® from the Transparency Committee in France
Exhibit 99.4	Press release dated February 6, 2007 FDA Grants Priority Review to Lovenox® (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for additional type of heart attack .